These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11877309)

  • 1. Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia.
    Casato M; Mecucci C; Agnello V; Fiorilli M; Knight GB; Matteucci C; Gao L; Kay J
    Blood; 2002 Mar; 99(6):2259-61. PubMed ID: 11877309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV and cryoglobulinemic vasculitis.
    Ferri C; Zignego AL; Giuggioli D; Sebastiani M; Cazzato M; Antonelli A; La Civita L; Fadda P; Longombardo G; Pileri S
    Cleve Clin J Med; 2002; 69 Suppl 2():SII20-3. PubMed ID: 12086259
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas.
    Zignego AL; Ferri C; Giannelli F; Giannini C; Caini P; Monti M; Marrocchi ME; Di Pietro E; La Villa G; Laffi G; Gentilini P
    Ann Intern Med; 2002 Oct; 137(7):571-80. PubMed ID: 12353944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.
    Agnello V
    Springer Semin Immunopathol; 1997; 19(1):111-29. PubMed ID: 9266635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies.
    Knight GB; Gao L; Gragnani L; Elfahal MM; De Rosa FG; Gordon FD; Agnello V
    Arthritis Rheum; 2010 Jul; 62(7):2152-9. PubMed ID: 20506150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC
    Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia.
    Agnello V; Zhang QX; Abel G; Knight GB
    Clin Exp Rheumatol; 1995; 13 Suppl 13():S101-4. PubMed ID: 8730487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Birmingham vasculitis activity score, disease extent index and complement factor C3c reflect disease activity best in hepatitis C virus-associated cryoglobulinemic vasculitis.
    Lamprecht P; Moosig F; Gause A; Herlyn K; Gross WL
    Clin Exp Rheumatol; 2000; 18(3):319-25. PubMed ID: 10895368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents].
    Ignatova TM; Chernova OA; Burnevich EZ; Milovanova SIu
    Klin Med (Mosk); 2014; 92(8):62-4. PubMed ID: 25790700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus-associated type II mixed cryoglobulinemia vasculitis complicated with membranous proliferative glomerulonephritis.
    Lo KY; Chen CY; Lee CS
    Ren Fail; 2009; 31(2):149-52. PubMed ID: 19212913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.
    Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P
    J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryoglobulinemic vasculitis.
    Ferri C; Mascia MT
    Curr Opin Rheumatol; 2006 Jan; 18(1):54-63. PubMed ID: 16344620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment].
    Gordovskaia NB; Kozlovskaia LV; Milovanova SIu; Ignatova TM; Korotchaeva IuV
    Ter Arkh; 2013; 85(6):78-84. PubMed ID: 23866603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
    Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
    Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
    Ignatova TM; Mukhin NA
    Ter Arkh; 2012; 84(11):81-8. PubMed ID: 23252255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus.
    Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM
    J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoproliferation in type II mixed cryoglobulinemia.
    Monteverde A; Ballarè M; Bertoncelli MC; Zigrossi P; Sabattini E; Poggi S; Pileri S
    Clin Exp Rheumatol; 1995; 13 Suppl 13():S141-7. PubMed ID: 8730495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Autoimmune and lymphoproliferative HCV-correlated manifestations: example of mixed cryoglobulinaemia (review)].
    Ghinoi A; Mascia MT; Puccini R; Ferri C
    G Ital Nefrol; 2004; 21(3):225-37. PubMed ID: 15285001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders.
    Realdon S; Pontisso P; Adami F; Trentin L; Noventa F; Ferrari A; Migliorato I; Gatta A; Alberti A
    J Hepatol; 2001 May; 34(5):723-9. PubMed ID: 11434619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.